Abstract

Infections take their greatest toll in early life necessitating robust approaches to protect the very young. Here, we review the rationale, current state, and future research directions for one such approach: neonatal immunization. Challenges to neonatal immunization include natural concern about safety as well as a distinct neonatal immune system that is generally polarized against Th1 responses to many stimuli such that some vaccines that are effective in adults are not in newborns. Nevertheless, neonatal immunization could result in high-population penetration as birth is a reliable point of healthcare contact, and offers an opportunity for early protection of the young, including preterm newborns who are deficient in maternal antibodies. Despite distinct immunity and reduced responses to some vaccines, several vaccines have proven safe and effective at birth. While some vaccines such as polysaccharide vaccines have little effectiveness at birth, hepatitis B vaccine can prime at birth and requires multiple doses to achieve protection, whereas the live-attenuated Bacille Calmette–Guérin (BCG), may offer single shot protection, potentially in part via heterologous (“non-specific”) beneficial effects. Additional vaccines have been studied at birth including those directed against pertussis, pneumococcus, Haemophilus influenza type B and rotavirus providing important lessons. Current areas of research in neonatal vaccinology include characterization of early life immune ontogeny, heterogeneity in and heterologous effects of BCG vaccine formulations, applying systems biology and systems serology, in vitro platforms that model age-specific human immunity and discovery and development of novel age-specific adjuvantation systems. These approaches may inform, de-risk, and accelerate development of novel vaccines for use in early life. Key stakeholders, including the general public, should be engaged in assessing the opportunities and challenges inherent to neonatal immunization.

Highlights

  • Despite the success of the Millenium Development Goal era from 2000 to 2015, during which the under five mortality rate was reduced by 53%, ~ 2 million infants under 6 months die annually due to infections [1]

  • Of the 5.9 million children under 5 years of age who died in 2015, 45% were in the first month of life [2]. Many of these deaths are attributed to vaccine preventable illnesses, occurring before protection is afforded by routine immunization given as part of the expanded program of immunization (EPI)

  • As with any vaccine approach, development of neonatal vaccines must take into account potential limitations, including: (a) need to establish safety, (b) lack of effectiveness of some vaccines in early life, (c) challenges of a translational path that typically starts with formulations optimized for adults, rather than generating formulations that are optimal for the young, and (d) potential blunting of neonatal Ab responses after maternal immunization

Read more

Summary

INTRODUCTION

Despite the success of the Millenium Development Goal era from 2000 to 2015, during which the under five mortality rate was reduced by 53%, ~ 2 million infants under 6 months die annually due to infections [1]. Of the 5.9 million children under 5 years of age who died in 2015, 45% were in the first month of life [2] Many of these deaths are attributed to vaccine preventable illnesses, occurring before protection is afforded by routine immunization given as part of the expanded program of immunization (EPI). In an effort to reduce the under 5-year old mortality rate further, to ≤25/1,000 live births by the end of 2030, a number of strategies are being explored and implemented as part of the sustainable development goal-3 These include maternal immunization, which, it shows great promise for a number of pathogens, including pertussis and influenza, is limited by safety and ethical concerns, and is of limited value for the ~2.6 million infants born preterm, prior to maternal antibody (Ab) transfer [3]. We review the rationale for neonatal immunization and highlight essential research areas, including the study of immune ontogeny and the development of vaccines optimized for early life administration

Rationale for Use of Vaccines in the Neonatal Period
LESSONS FROM IMMUNE ONTOGENY
Hepatitis B Vaccine
Future vaccine targets
CLINICAL STUDIES OF OTHER VACCINES AT BIRTH
Haemophilus Influenza Type B
Pneumococcal Conjugate Vaccine
Enhancing Current Vaccines
Development of Adjuvants for Early Life Immunization
Mucosal Vaccine Development
Systems Biology
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call